Navigation Links
New prostate cancer test gives more accurate diagnosis
Date:4/6/2011

CHICAGO --- In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false positives compared to the two currently available commercial PSA tests, according to newly published research from Northwestern Medicine.

The only currently available Food and Drug Administration-approved screening tests for prostate cancer result in a high number of false positives and lead to unnecessary biopsies and possible over-detection and over-treatment of indolent cancer which never would have caused suffering or death.

PSA stands for prostate-specific antigen, a substance whose elevated levels can indicate prostate cancer but can also be caused by prostate inflammation or enlargement or other conditions. Its lack of specificity can result in unnecessary biopsies.

"This new test is more specific and accurate than the currently available blood tests for early prostate cancer detection," said lead investigator William Catalona, M.D., director of the clinical prostate cancer program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "This will focus on the detection of more life-threatening prostate cancers and reduce unnecessary biopsies in men 50 years of age and older."

Catalona, known as the father of the PSA screening, was the first to show in 1991 that a simple blood test measuring PSA levels could be used to detect prostate cancer. He is a professor of urology at Northwestern's Feinberg School of Medicine and a urologist at Northwestern Memorial Hospital.

The study, which will be published in the May issue of the Journal of Urology, followed 900 patients from 10 sites, including Northwestern. The results showed the new screening test, a simple blood test called the Pro-PSA test, is particularly useful for patients with a normal prostate exam whose PSA is 2 to 10, a range considered the diagnostic gray zone because most men with higher levels have prostate cancer and most men with lower levels do not.

The Pro-PSA test measures a more specific PSA subform called (-2) Pro-PSA. The test becomes even more accurate when its results are analyzed with a mathematical formula that provides an overall Prostate Health Index. (The formula divides the Pro-PSA number by the free-PSA. Then the quotient of the two is multiplied by the square root of the total PSA. )

"The logic behind the formula is that the higher the Pro-PSA and the total PSA and the lower the free-PSA, the more likely the patient has aggressive prostate cancer," Catalona said.

The new Pro-PSA test was recently approved for commercial use in Europe, Catalona noted. "The FDA is currently reviewing our data from the study, and I'm hopeful that it will be approved in the United States as well," he said.


'/>"/>

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. U-M scientists find potential driver of some aggressive prostate cancers
2. MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men
3. Scientists identify KRAS rearrangements in metastatic prostate cancer
4. Digoxin may be a possible treatment for prostate cancer
5. Heart drug cuts prostate cancer risk; holds potential for therapeutic use
6. Prostate Cancer Screening Doesnt Cut Death Rates: Study
7. New tool allows for an alternate method of prostate cancer diagnosis
8. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
9. Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study
10. Long-term study: Robot-assisted prostate surgery is safe
11. Statins make radiation more effective at curing prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... , ... July 24, 2017 , ... A CDC study shows that, although people are ... Caucasians (ages 18 to 29), had at least one case of sunburn within the past ... which causes people to ignore the issue. However, only recently have people become conscientious of ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 NCSL International Workshop ... theme focuses on the new ISO/IEC 17025 standards. This marks the first time ... and calibration will be changed. , As an exhibitor, METTLER TOLEDO will ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited ... plastic surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As ... the world, Allergan is bringing a newly defined structure to the aesthetics market. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... CURE announced that they have enrolled over 100,000 children in their treatment program. ... born every year in areas where treatment is limited or non-existent. Without intervention, ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology: